<SEC-DOCUMENT>0001104659-21-013616.txt : 20210208
<SEC-HEADER>0001104659-21-013616.hdr.sgml : 20210208
<ACCEPTANCE-DATETIME>20210208141734
ACCESSION NUMBER:		0001104659-21-013616
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210208
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20210208
DATE AS OF CHANGE:		20210208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anchiano Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		21600811

	BUSINESS ADDRESS:	
		STREET 1:		5 KIRYAT HAMADA ST
		STREET 2:		PO BOX 45032
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9777401
		BUSINESS PHONE:		972-2-5486555

	MAIL ADDRESS:	
		STREET 1:		5 KIRYAT HAMADA ST
		STREET 2:		PO BOX 45032
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9777401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm215756d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): February 8, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ANCHIANO THERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; text-align: center; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>State of Israel</B></FONT></TD>
<TD STYLE="text-align: center; vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center; width: 31%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>001-38807</B></FONT></TD>
<TD STYLE="text-align: center; vertical-align: bottom; width: 1%">&nbsp;</TD>
<TD STYLE="vertical-align: top; text-align: center; width: 31%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>81-3676773</B></FONT></TD></TR>
<TR>
<TD STYLE="text-align: center; vertical-align: top"><B>(State or other jurisdiction</B> <B><BR>
of incorporation)</B> </TD>
<TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="text-align: center; vertical-align: top"><B>(Commission<BR>
</B> <B>File Number)</B> </TD>
<TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
<TD STYLE="text-align: center; vertical-align: top"><B>(IRS Employer<BR>
</B> <B>Identification No.)</B> </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="text-align: center; vertical-align: top; width: 51%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>One Kendall Square, Building 1400E, Suite
        14-105</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Cambridge, MA</B></P></TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 48%"><FONT STYLE="font-size: 10pt"><B>02139</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (857) 259-4622</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Former name or former address, if changed
since last report) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR>

<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&nbsp;</FONT></TD></TR>

<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</FONT></TD></TR>

<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
<TD STYLE="width: 3%">&nbsp;</TD>
<TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD>
<TD STYLE="vertical-align: top; width: 94%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))&nbsp; &nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="border: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center; width: 39%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD>
    </TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">American Depositary Shares, each representing five ordinary shares, no par value per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANCN</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Capital Market</FONT></TD>
    </TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary shares, no par value per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; background-color: #FEFEFE; padding-top: 1.5pt; padding-right: 1pt; padding-left: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq Capital Market*</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Not for trading; only in connection with the registration
of American Depositary Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anchiano Therapeutics Ltd. (&ldquo;<B>Anchiano</B>&rdquo; or
the "<B>Company</B>") announces that it will hold a Special Meeting of Shareholders (the &ldquo;<B>Special&nbsp;Meeting</B>&rdquo;)
at the law offices of Goldfarb Seligman &amp; Co., Ampa Tower, 98 Yigal Alon Street, 36th floor, Conference Room 36-1, Tel Aviv,
Israel on March 15, 2020, at which meeting Anchiano shareholders will be asked to approve the merger (the &ldquo;<B>Merger</B>&rdquo;)
of CMB Acquisition Ltd., a company organized under the laws of the State of Israel and a wholly-owned subsidiary of Anchiano (&ldquo;<B>Merger
Sub</B>&rdquo;) into Chemomab Ltd., company organized under the laws of the State of Israel (&ldquo;<B>Chemomab</B>&rdquo;), pursuant
to the Agreement and Plan of Merger, dated December 14, 2020, by and among Anchiano, Chemomab and Merger Sub (the &ldquo;<B>Merger
Agreement</B>&rdquo;), as well as the other matters set forth below. Anchiano will distribute a definitive proxy statement/prospectus,
which will include the full version of the proposed resolutions, and a proxy card to all holders of Anchiano&rsquo;s ordinary
shares and holders of Anchiano&rsquo;s American Depositary Shares at the close of business on February 5, 2021, the record date
for the Special Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agenda for the Special Meeting is as follows: (1) to approve
the consummation of the Merger and the other transactions contemplated&nbsp; by the Merger Agreement, including the issuance of
Anchiano ordinary shares, to be represented by ADSs, at the effective time of the Merger to the securityholders of Chemomab; (2)
to approve the issuance of such number of Anchiano ordinary shares (including ordinary shares represented by ADSs) in the private
placement financing, as described in the definitive proxy statement/prospectus, as would yield at least $30.0 million and up to
$50.0 million of aggregate gross proceeds to Anchiano; (3) to approve and adopt Anchiano&rsquo;s amended and restated articles
of association, effective upon the effective time of the Merger, which among other things will (i) increase the registered share
capital of Anchiano from 500,000,000 ordinary shares, without par value, to 650,000,000 ordinary shares, without par value, (ii)
effect a reverse split of Anchiano&rsquo;s ordinary shares at a ratio in the range between 1-for-2 to 1-for-4, inclusive, with
such ratio to be determined in the discretion of Anchiano&rsquo;s board of directors, (iii)&nbsp;amend the manner in which directors
are elected to a classified board format, (iv) change the name of Anchiano from &ldquo;Anchiano Therapeutics Ltd.&rdquo; to &ldquo;Chemomab
Therapeutics Ltd.&rdquo; or such other name as may be approved by Chemomab and the Israeli Registrar of Companies and (v) make
such other changes as are set forth in the amended and restated articles of association which will be attached as an annex to the
definitive proxy statement/prospectus; (4) to approve the form of indemnification agreement for directors and officers of Anchiano
effective upon the effective time of the Merger, and to authorize the execution and delivery of such indemnification agreement
with all directors of Anchiano to be in office immediately following the effective time of the Merger or thereafter elected or
appointed to the board of directors of Anchiano; (5) to approve an amendment to Anchiano&rsquo;s Compensation Policy to remove
the limit on the annual premium for directors and officers insurance; (6) to approve an amendment to the compensation terms of
the current and future directors of Anchiano, and related amendments to Anchiano&rsquo;s Compensation Policy; and (7) to transact
any other business that may properly come before the Special Meeting or any continuation, adjournment or postponement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward Looking Statements</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This report contains &ldquo;forward-looking statements&rdquo;
within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things,
statements regarding the structure, timing and completion of the proposed merger.&nbsp;Any statements contained in this communication
that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are
based upon the Company&rsquo;s current expectations. Forward-looking statements involve risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Because such statements deal with future
events and are based on the Company&rsquo;s current expectations, they are subject to various risks and uncertainties and actual
results, performance or achievements of the Company or the combined company could differ materially from those described in or
implied by the statements in this report, including: the risk related to the Company&rsquo;s ability to complete the merger on
the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related
to the merger agreement and risks and uncertainties related to the failure to timely or at all obtain shareholder approval for
the transaction; the execution of definitive agreements with certain existing Chemomab shareholders including risks and uncertainties
related to the satisfaction of the closing conditions related to the financing; risks related to the combined company&rsquo;s ability
to correctly manage its operating expenses and its expenses; risks related to the market price of the Company&rsquo;s ADSs relative
to the exchange ratio; unexpected costs, charges or expenses resulting from the transaction; potential adverse reactions or changes
to business relationships resulting from the announcement or completion of the proposed merger transaction; combined company&rsquo;s
plans to develop and commercialize its product candidates, including CM-101 and RAS; and the requirement for additional capital
to continue to advance these product candidates, which may not be available on favorable terms or at all. In addition, there can
be no assurance that the Company will be able to complete the transactions contemplated by the merger agreement or related transactions.
Additional risks and uncertainties relating to the Company and its business can be found under the caption &ldquo;Risk Factors&rdquo;
and elsewhere in the Company&rsquo;s filings and reports with the SEC, including in the Company&rsquo;s Annual Report on Form 10-K
for the year ended December 31, 2019 filed with the SEC on March 17, 2020 as updated by its Quarterly Reports on Form 10-Q for
the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, filed with the SEC on May 7, 2020, August 14, 2020 and
November 16, 2020, respectively, and its other subsequent filings with the SEC. The Company expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change
in the Company&rsquo;s expectations with regard thereto or any change in events, conditions or circumstances on which any such
statements are based.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional Information and Where You Can Find It</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the
proposed transactions between the Company and Chemomab, the Company filed <FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">a
registration statement containing a proxy statement and prospectus with the SEC</FONT>. This communication is not a substitute
for the proxy statement or any other documents that the Company may file with the SEC or send to its shareholders in connection
with the proposed transactions. Before making any voting decision, investors and securityholders are urged to read the proxy statement
and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become
available because they will contain important information about the proposed transaction and related matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">You may obtain free copies
of the proxy statement and all other documents filed or that will be filed with the SEC regarding the proposed transaction at the
website maintained by the SEC at www.sec.gov. Once filed, the proxy statement will be available free of charge on the Company&rsquo;s
website at <U>https://www.anchiano.com/</U>, by contacting the Company&rsquo;s Investor Relations at info@anchiano.com or by phone
at 857-259-4622 or by mail at Investor Relations, Anchiano Therapeutics Ltd., One Kendall Square, Building 1400E, Suite 14-105,
Cambridge, MA 02139.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Participants in Solicitation</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company, Chemomab
and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the
holders of the Company&rsquo;s ordinary shares in connection with the proposed transaction. Information about the Company&rsquo;s
directors and executive officers is set forth in the Company&rsquo;s Definitive Proxy Statement for its 2020 Annual meeting, which
was filed with the SEC on April 6, 2020. Other information regarding the interests of such individuals, as well as information
regarding Chemomab&rsquo;s directors and executive officers and other persons who may be deemed participants in the proposed transaction
<FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">are included in the proxy statement and prospectus
referred to above</FONT>. You may obtain free copies of these documents as described in the preceding paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-Solicitation</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This report will not
constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor
will there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: left">&nbsp;</TD>
<TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ANCHIANO THERAPEUTICS LTD.</B></FONT></TD></TR>
<TR>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR>
<TD STYLE="text-align: left; vertical-align: top; width: 52%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date: February 8, 2021</B></FONT></TD>
<TD STYLE="vertical-align: top; text-align: left; width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B></FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; text-align: left; vertical-align: top; width: 44%">/s/ Neil Cohen </TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Neil Cohen</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left">&nbsp;</TD>
<TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: Interim Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
